NCT01341470 is a Phase 1 clinical trial of LY2495655 in Healthy Volunteer, sponsored by Eli Lilly and Company.

Who is sponsoring NCT01341470?

NCT01341470 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT01341470?

Interventions in NCT01341470: LY2495655, Placebo.

What condition does NCT01341470 study?

NCT01341470 studies Healthy Volunteer.

Is NCT01341470 still recruiting?

NCT01341470 is currently completed. Last updated 15 March 2019.

Are results published for NCT01341470?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-03-15 · How we verify

NCT01341470

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2495655 in Japanese Subjects

Completed Phase 1 Results posted Last updated 15 March 2019

What this trial tests

Phase 1 trial testing LY2495655 in Healthy Volunteer in 47 participants. Completed in 1 May 2012.

Timeline

1 May 2011

Primary endpoint
1 May 2012

1 May 2012

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	treatment
Enrollment	47
Start date	1 May 2011
Primary completion	1 May 2012
Estimated completion	1 May 2012
Sites	1 location across United States

Drugs / interventions tested

LY2495655 — full drug profile →
Placebo

Conditions studied

Healthy Volunteer — all drugs for Healthy Volunteer →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

Adults 24 to 85, any sex, with Healthy Volunteer. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants With Clinically Significant Effects
Time frame: Baseline to study completion (up to 135 days)
Clinically significant effects are defined as treatment emergent adverse events (TEAEs) which in the opinion of the investigator are thought to be possibly related to study drug. A summary of serious and all other non-serious adverse events (whether or not related to study drug) is located in the Reported Adverse Events module.

Sponsor's own description

The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of LY2495655 administered subcutaneously and intravenously in Japanese subjects.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders.
Smith RC, Lin BK. · · 2013 · cited 118× · PMID 24157714 · DOI 10.1097/spc.0000000000000013
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs.
Rodgers BD, Ward CW. · · 2022 · cited 68× · PMID 34520530 · DOI 10.1210/endrev/bnab030
Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions.
Wetzlich B, Nyakundi BB, Yang J. · · 2025 · cited 37× · PMID 39340593 · DOI 10.1007/s11010-024-05120-y

Verify or expand the search:

Other recruiting trials for Healthy Volunteer

Currently open trials in the same condition.

NCT06274749 — Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Mask · NA · recruiting
NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
NCT06845176 — Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery · NA · recruiting
NCT07439263 — Single Ascending Dose Study of HB2198 in Healthy Participants · Phase 1 · recruiting
NCT07220122 — Impact of Exogenous Ketones on Breathing in Healthy Volunteers · EARLY_PHASE1 · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01341470 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 15 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01341470.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing